Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Rae Cook/Axios

The antiviral pill that showed promising results against severe COVID-19 was originally developed at Emory University with $35 million of taxpayer grants.

Why it matters: The federal government consequently owns rights to some of the molnupiravir's patents, which could factor into future purchasing agreements with Merck, which sells the drug.

Flashback: Emory University researchers conducted early-stage testing on molnupiravir from 2013 to 2020 with funds from the National Institutes of Health and Defense Department.

  • Emory then licensed the drug to Ridgeback Biotherapeutics at the start of the pandemic so the drug could get into human clinical trials.
  • The federal government declined to put more money into backing the drug until there was more data.
  • Merck then bought the exclusive rights to sell and manufacture the drug worldwide.
  • Each major patent application for molnupiravir cites federal funding, which means "the U.S. government co-owns molnupiravir and has rights to demand availability at a reasonable price," according to Luis Gil Abinader, a researcher at Knowledge Ecology International, a group that studies intellectual property.

By the numbers: The U.S. government paid $712 per treatment course in June. Each course requires patients to consume 40 pills over five days, so the government paid $17.80 per pill.

  • That is at least four times cheaper than remdesivir, an IV drug that treats COVID-19. But two researchers estimate molnupiravir could be made at $20 per course, or $0.50 per pill, and still include a 10% profit margin.

What they're saying: Merck did not answer questions about federal funding of molnupiravir.

  • The company said it will "implement a tiered pricing approach based on World Bank data that recognizes countries' relative ability to finance their health response to the pandemic."
  • Merck also entered into voluntary licensing agreements with "Aurobindo Pharma, Cipla, Dr. Reddy's Labs, Emcure Pharmaceuticals, Hetero Labs, Sun Pharmaceuticals, Torrent Pharmaceuticals and Viatris, and each will set its own price for 104 countries globally."

The big picture: Federal dollars were also used to back the development of Moderna's COVID-19 vaccine, making that another example where the government owns rights to significant COVID-related intellectual property.

The bottom line: The FDA still needs to validate molnupiravir's results, but "even if one includes the cost of manufacturing the pills, a price one-fifth that [$712] should be sufficient to assure a reasonable return on investment," pharmaceutical author and journalist Merrill Goozner wrote yesterday.

Go deeper

16 hours ago - Health

Study reveals disparities in hospitals' COVID funds

Hospitals that received the most federal coronavirus relief money were disproportionately academic-affiliated and had higher pre-pandemic assets, according to a new study published in JAMA Health Forum.

Yes, but: Those hospitals were also more likely to have had higher numbers of COVID cases.

18 hours ago - Health

A choose-your-own COVID booster adventure

Illustration: Annelise Capossela/Axios

COVID-19 boosters are now available for many adults who want one.

  • But the various combinations of who should get one and when now that mixing and matching shots got the OK just made the process much more complex.

Why it matters: The CDC has yet to issue final clinical guidance but the panel's discussions and interim clinical considerations last week show picking whatever shot they want leaves room for confusion.

22 hours ago - Health

DeSantis touts bonuses for unvaccinated police who relocate to Florida

Florida Gov. Ron DeSantis speaks during a press conference Friday in Kissimmee, Fla. Photo: Paul Hennessy/SOPA Images/LightRocket via Getty Images

Gov. Ron DeSantis announced plans Sunday to "hopefully sign" legislation to provide a $5,000 bonus to police officers who relocate to Florida in order to avoid COVID-19 vaccine mandates.

Why it matters: The governor's pledge during an appearance on Fox News comes amid escalating tensions with the Biden administration over its upcoming vaccine requirement for federal workers.